Science Videos

Johns Hopkins Psychiatry Grand Rounds | Rare Glutamate Receptor Variants and Schizophrenia

The grand rounds presentation focused on rare variants in the GRIA3 gene, an X‑linked AMPA‑type glutamate receptor, and their role in schizophrenia. Using a multigenerational family with multiple affected members, researchers identified ultra‑rare GRIA3 mutations absent from tens of thousands of controls, highlighting a >20‑fold increase in disease odds. The talk placed these findings within the broader genetic architecture of schizophrenia, where common polygenic risk, copy‑number deletions (e.g., 22q11.2) and rare high‑impact variants together shape susceptibility, with glutamate‑related genes emerging as a recurrent theme. Key data included a meta‑analysis of 24,000 cases and 97,000 controls that ranked GRIA3 among the top ten significant genes. Functional work in vitro demonstrated that several schizophrenia‑associated variants either reduce overall protein expression, impair surface trafficking, or alter receptor kinetics—some causing loss of function, others producing gain‑of‑function phenotypes such as increased glutamate response or prolonged channel opening. Parallel studies in mouse models will employ single‑cell transcriptomics and behavioral assays to map how these molecular disruptions translate into neurocognitive deficits. The presenter cited precedent where rare‑variant discoveries have directly informed treatment—cystic fibrosis, spinal muscular atrophy, and other monogenic disorders—suggesting a similar translational pathway for schizophrenia. By characterizing GRIA3 variants, the project aims to uncover mechanistic links that could be targeted by novel glutamatergic modulators, potentially addressing the unmet need for therapies that improve negative symptoms and treatment‑resistant cases. Overall, the work underscores the importance of integrating rare‑variant genetics with functional neuroscience to refine disease models and pave the way for precision psychiatry. If successful, it could shift therapeutic strategies from dopamine‑centric approaches toward interventions that normalize excitatory synaptic signaling.